On Thursday, Abivax ADR hit an important technical milestone, with its Relative Strength (RS) Rating rising into the 90-plus percentile with an upgrade to 99, an increase from 86 the day before.
How To Use Stock Charts To Stay Profitable And Protected
IBD's unique RS Rating identifies market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research reveals that the best stocks often have an 80 or higher RS Rating as they launch their biggest price moves.
Abivax ADR has climbed more than 5% past an 11.60 entry in a first-stage consolidation, meaning it's now out of a proper buy range. Look for the stock to create a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
Abivax ADR showed 0% earnings growth in its most recent report, while sales growth came in at -16%.
The company earns the No. 91 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Harmony Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
